Isconova AB of Sweden has appointed Sven Andréasson as its new chief executive with a remit to progress the company’s vaccine adjuvant portfolio. Mr Andréasson was previously chief executive of Beta-Cell NV in Belgium and before that, CEO of Active Biotech AB.
Based in Uppsala, Isconova develops vaccines for the human and veterinary markets. Its partners include Crucell (Johnson & Johnson), Pfizer Inc and Merck & Co Inc.
Isconova announced the appointment on 23 February 2012.
Copyright 2012 Evernow Publishing Ltd